$1,099 – $2,699

13th World Congress on Dementia and Alzheimer's Disease (AAC)

Event Information

Share this event

Date and Time



Venue will be informed to the Registered Participants



View Map

Refund Policy

Refund Policy

No Refunds

Event description


13th World Congress on Dementia and Alzheimer's Disease

About Conference

We take immense pleasure and honour to welcome all the participants across the world to attend the esteemed 13th World Congress on Dementia and Alzheimer’s Disease slated on September 16-17, 2019 at Paris, France.

Dementia is a broad category of brain diseases that causes a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning.

Dementia 2019 is an international congress which expects more than 50 speakers and more than 100 participants from all across the world. Dementia 2019 will provide you a wonderful exposure to the latest research and technology developing in the field of Dementia and Alzheimer’s disease. This is the perfect stage to develop and nourish your research interest and participate in the scientific discussion with global scientists. Along with this, Dementia 2019 will help the participants develop international academic and business network.

The main focus of Dementia 2019 will be on Alzheimer’s disease, Dementia, Imaging Techniques associated with Biomarkers, various animal models, Geriatrics and Cognitive Disorder, Pathophysiology, Care practice and Awareness, Current Trends and Awareness in Dementia and Alzheimer.

We welcome all the renowned and aspiring researchers, scientists and business delegates, who are significantly putting their effort to improve the life of population with Dementia.

Reasons to attend:

-Meet eminent experts and personalities working in the field of Neuroscience and Neurology
-Enhance your knowledge
-Share your innovative ideas
-Worldwide Networking and Career Opportunities

This platform will give you an international stage to conduct demonstrations, workshops, and symposiums to showcase your services and products. Dementia 2019 will avail you a chance to distribute information and to meet potential national and international delegates. Participants can approach the invited scientists to explore the new product line possibility and exchange ideas of developing novel therapeutics or products. World-renowned speakers, the most recent researches, innovations, and novel updates in the filed of Dementia are hallmarks of this congress.

Target Audiences:

· Presidents
· Directors
· Neurologists
· Neuroscientists
· Neurosurgeons
· Neurology Professors
· Neurology Assistant and Associate Professors
· Post doctorates and Doctorates
· Dementia Researchers
· Medical College and Hospitals
· Business Entrepreneurs
· Training Institutes
· Software developing companies
· Medical Devices Manufacturing Companies
· Data Management Companies
· Pharmaceutical industries and Biotech Company
· Dementia community, society and associations
· Other experts in Dementia and dementia care

Scientific Sessions

Dementia: An Underlying Disease- Dementia is a broad category of brain diseases that causes a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Alzheimer’s disease is the most common type of disease which covers 50-70% cases. The common symptoms of Dementia include emotional constraints, problem in finding words, lack of motivation etc. The severity of Dementia increases with the person’s age. The other common types of diseases which include Dementia are Vascular dementia, Lewy body dementia and Frontotemporal dementia. Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015, past results shown 35.66 million population lived with Dementia worldwide in year 2010, with numbers expected to nearly double each twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

Vascular Dementia and Stroke

Frontotemporal Dementia

Lewy body Dementia

Mixed Dementia

Clinical Stages in Dementia progression

Signs and Symptoms of Dementia

Diagnosis of Dementia

Alzheimer's Disease- Alzheimer's disease is the most common category of Dementia. It is a chronic neurodegenerative disorder and caused by brain cell death. The symptoms of brain cell death are memory loss, disorientation and cognitive decline. The size of the brain shrinks and the nerve cells and attachments in the tissues progressively reduced, which cannot be diagnosed in the living brain affected by Alzheimer's disease, post-mortem / autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called Beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from a disintegration of second protein, called Tau. There are no existing treatments or preventive measures to stop or cure Alzheimer’s. Most of patients with Alzheimer’s are above 65 years of age but 4-5% cases are of early onset Alzheimer’s.

Stages of Alzheimer’s

Diagnosis of Alzheimer's

Cholinergic and Amyloid Hypothesis in Alzheimer's

Genetics in Alzheimer's

Clinical Studies of Alzheimer’s

Advanced Tests and Treatments

Parkinson’s Disease- Parkinson's disease Dementia is a cognitive decline in thinking and reasoning that develops in the person diagnosed with Parkinson's disease at least a year earlier. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms. Hence this conference will provide a platform to discuss the problem.

Key risk factors of Parkinson’s Disease

Multiple system Atrophy (MSA)

Progressive Supranuclear palsy

Neuropsychiatry of Parkinson’s Disease

Neuropathophysiological Symptoms of Parkinson’s

Clinical Diagnosis of Parkinson’s Disease

Neurodegenerative Diseases- Neurodegeneration is the progressive loss of structure or function of neurons, including death of the nerve cells. It can cause your brain and nerves to deteriorate over time. The neurological conditions in which the Dementia occurs include some disorders like Parkinson's disease, Normal Pressure Hydrocephalus, Huntington's disease, and Creutzfeldt-Jakob disease (CJD). These diseases mimic Dementia or has Dementia as a major sign in the disease. The genetic factors are responsible for the establishment of disorders like Parkinson’s disease, Down Syndrome, Creutzfeldt-Jakob disease, Normal Pressure Hydrocephalus. The other factors for Dementia include physical factors like head injuries and Traumatic brain injuries.


Huntington’s Disease

Normal Pressure Hydrocephalus

Creutzfeldt-Jakob Disease

Spinal Muscular Atrophy

Down syndrome linked with Dementia

Multiple Sclerosis

Epilepsy and Convulsions

Clinical Manifestations

Cutting Edge Technologies in Prevention and Treatment

Vascular Dementia- Vascular dementia is the second most common type of Dementia after Alzheimer’s Disease. It is also called as Multi-Infarct Dementia (MID) and Vascular Intellectual Impedance (VCI), is caused by issues in the supply of blood to the mind, normally a progression of minor strokes. Dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain. People with dementia give dynamic subjective hindrance, intensely or sub acutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Dementia can be caused by ischemic or haemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gurus.

Vascular Dementia and Stroke

Clinical Phenotype and Pathogenetic Mechanisms

Neuronal Dysfunction in Vascular Dementia

Clinical Diagnosis of Vascular Dementia

Advancements in the Treatments of Vascular Dementia

Traumatic Brain injury- Traumatic brain injury (TBI) is an unpredictable damage with a wide range of side effects and incapacities. The effect on a man and his or her family can demolish. The reason for this site is to teach and enable guardians and survivors of awful mind wounds. This site expects to facilitate the progress from stun and lose hope at the season of cerebrum damage to adapting and critical thinking. The side effects of mind wounds and the country's best awful cerebrum damage recovery focuses and asset data.

Repercussions of Traumatic brain Injury

Cerebrum Damage

Preventive Measures

Diagnostic methods for Brain Injuries

Care and Treatment for Traumatic Brain Injuries

Neuropharmacology- The action of drug on the nervous system and the neural mechanisms through which they influence behaviour is studied in neuropharmacology. Studying these interactions will help the researchers in developing drugs to treat neurological disorders, psychological disorders, pain, addiction and other diseases. Drug development in Dementia and Alzheimer’s Disease is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signalling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies. Rigorous clinical trials on Dementia drugs are continuing in USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. The most of drugs are in second and third phases. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offers positivity to discover new approaches in curing Dementia.

Drug development in Dementia

Clinical Trials in Dementia

Vaccine development against Beta-Amyloid

Animal Models and Translational Medicines

Anticonvulsant Drugs for Treatment

Beta-Amyloid Polymerization and Inflammation Inhibitor

Geriatrics Dementia and Cognitive Disorder- Geriatrics or geriatric medication may be a specialty that focuses on health care of older people. It aims to push health by preventing and treating diseases and disabilities in older adults. there's no set age at that patients are also underneath the care of a specialist or geriatric MD; a MD United Nations agency makes a specialty of the care of older people. Rather, this call is set by the individual patient’s needs, and therefore the availableness of a specialist. It’s vital to notice the distinction between gerontology, the care of aged people, and geriatrics, that is that the study of the aging method itself.
Cognitive disorders square measure a class of mental state disorders that primarily influence learning, memory, perception, and drawback determination, and embody blackout, dementia, and delirium. Whereas anxiety disorders, mood disorders, and psychotic disorders can even have an effect on psychological feature and memory functions, the DSM-IV-TR doesn't contemplate these psychological feature disorders, because loss of cognitive function is not the primary (causal) symptom. Causes vary between the various sorts of disorders however most include damage to the memory parts of the brain. Treatments rely on however the disorder is caused. Medication and therapies square measure the foremost common treatments but, for a few sorts of disorders like amnesia, treatments will suppress the symptoms however there is presently no cure.

Neuroepigenetics- Neuroepigenetics is the field in Neurobiology that replaces the conventional thoughts on heritable epigenetic mechanisms, which involves in histone and chromatin modification which results in the variable expression of genes in the CNS. The numerous Neuroepigenetic mechanisms have been involved in several neurological and neurodegenerative diseases for the regulation of various epigenetic mechanisms. All the mechanisms in epigenetics will have a biochemical characteristic such that it helps in regulation process. The basic principle of Neuroepigenetics is that once DNA methylation patterns are established upon the genome in terminally differentiated cells, those modifications are permanent and essentially immutable. Other epigenetic molecular mechanisms are also in play in neurons. Some are ATP-dependent chromatin remodelling, genomic imprinting, SNF2 chromatin remodelling.

Genome-wide Analysis of DNA and RNA

Epigenetic Mechanisms

Biochemical Mechanisms

CNS Epigenome- Therapeutic Implications

Role of Amyloid Protein in Alzheimer’s and Dementia- The amyloid plaques and neurofibrillary tangles formation are thought to contribute to the degradation of the neurons (nerve cells) in the brain and the subsequent symptoms of Alzheimer's disease.

Amyloid Plaques: One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in brain. Amyloid generally indicates protein fragments that the body produces normally. Beta amyloid is a protein fragment from an amyloid precursor protein (APP). In a healthy brain, these protein fragments are broken down and get eliminated. In Alzheimer, the fragments get accumulated to form hard & insoluble plaques.
Neurofibrillary tangles are insoluble twisted fibres found inside the brain's cells, consisting primarily of a protein called tau, which forms structure called a microtubule. Transport of nutrients and other important substances from one part of the nerve cell to another done by help of microtubule. In Alzheimer's disease, the tau protein is abnormal and results in collapse of the microtubule structures.
This session includes Amyloid Protein and Alzheimer’s Disease, Amyloid beta metabolism in Alzheimer’s, Brain accumulation of toxic amyloid beta, Amyloid Plaques and Neurofibrillary Tangles, Amyloid Neuroimaging and biomarkers, Amyloidosis and Neurodegeneration, The amyloid hypothesis and potential treatments, Amyloid beta deposition, cognition and brain volume.

Beta-Amyloid metabolism in Alzheimer’s

Amyloid Plaques

Neurofibrillary Tangles

Amyloid Neuroimaging and Other Diagnostic Methods

Demyelinating Diseases

Potential Treatments

Bioinformatics Approach for Dementia- Bioinformatics advent can be used to regulate and evaluate data from the current high-throughput research technologies and render means for novel discoveries in the field of neurodegenerative diseases. It is reported that there is a very little published data on Epigenomics. It is said that the data are obtained from high through put technologies in screening of human brain. These data intend the upcoming researchers to know and design their experiments. The Data Mining plays an important role in the prediction of the disorder, where the actual data is compared with the real data and the results are interpreted. The Transcriptomics and Proteomics studies has also been carried out providing necessary solutions for the problems.

Proteomics in Dementia

Transcriptomics in Dementia

Epigenomics of Dementia

Data Mining Methods for Diagnosis of Dementia

Gene ontology and Genome wide screening Approach towards Dementia

Recent Advancements in the Diagnosis of Dementia- The assessment of Dementia in needed to rule out similar symptoms showing to such diseases such as depression, delirium which is curable. It is necessary to provide time to Dementia patients to plan future and make them literate about the possible effects in the future. There are various tests for diagnosing Dementia such as Mini Mental State Examination (MMSE), Mental Score Test, Trail Making Test. MMSE test include series of exercises in which various problems are checked with memory, speech, ability to respond. Blood test is also done to check levels of vitamin B12 and Thyroid hormones, which may be responsible. Brain scans such as MRI and CT scans used for checking brain tumour and Strokes in Vascular Dementia. Neurology gatherings talked rigorously on Dementia Diagnosis and it is always misleading to different conditions like Parkinson’s' disease. Hence discovery and establishment of new methodologies and techniques for analysis is in the urge for the Dementia society for dependable diagnosis methods.

Brain MRI scan techniques

Neurophysiological Testing

Neuro imaging

Biomarkers for diagnosis

Mini mental state Examination (MMSE)

Geriatric Depression Scale

Mental Score Test

Case Reports in Dementia- The goal of much of the research activity in dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently under diagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important, because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.

AIDS associated Dementia Case Report

Patients living in care

Epileptic seizures and Dementia

Hospice person with Cancer and Dementia

Treatment Modalities for Dementia- Treatment modality is a method that is followed to treat a patient suffering from a disease condition. The treatment modalities have three main approaches, which includes medical, psychological and sociocultural approaches. The most important consideration is that, in practice, no single treatment is considered sufficient for the treatment of Dementia. By now the combination therapy which involves the use of two or more drugs proves to be efficient. The other treatment methods which involve the stem cell therapy and gene therapy has now created the spotlight in the Dementia Treatment. Hence the advanced treatment methods can be discussed in the conference.


Combination Therapy

Neural Stem cell Treatment

Immuno Therapy

Adjunct Therapy

Lamotrigine Therapy

Animal-assisted Therapy

Dementia Care, Practice and Awareness- Dementia is predominant disorder that affects a greater number of people around the world. Diagnosis of the patient with Dementia frightens the person affected by the syndrome, their family members and caretakers. Better understanding about public awareness of Dementia aids more effective health and social policies. Dementia patients need assistance and full-time care as much as drugs. Some common care practices in Dementia are assistance in food and fluid consumption, pain management, social engagement ensuring safety and security of Dementia patients. Main aim of care practices is to ensure cut in hospitalization and psychotropic drugs. Understanding patient’s mood changes, particular behaviour, speech problems and help in rectifying them. Dementia patients need end of life care, so qualified nursing staff is needed. Few care practices which are used are indoor and outdoor activities, visual and audio stimulation, Art therapy. Care practices in Dementia have been critical to engage in International Dementia meetings. In need to evolve in Dementia care world gathering and genuine talks on Dementia care is required. The Dementia conference discusses public awareness as well as care practices to achieve higher rate of early diagnosis and to decrease the distress among the patient, family and caregivers.

Dementia Nursing

Psycho-Social Interventions

Cognitive Training

Dementia Management

Dementia Care Advances using Cloud Technology

Assistive Health Care

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:
- Multiple participant discounts
- Price quotations or visa invitation letters
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)
- Event sponsorship

Prices may go up any time. Service fees included in pricing.
This event is brought to you by:
Allied Academies - NewYorkEventsList


Share with friends

Date and Time


Venue will be informed to the Registered Participants



View Map

Refund Policy

No Refunds

Save This Event

Event Saved